Sector News

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

July 3, 2022
Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

The program launched during Nurses Week and aims to ensure that all nurses are aware of the link between Type 2 diabetes and ASCVD and how they can better educate their patients with Type 2 diabetes of that link and the dangers involved. In addition to ASCVD, people with Type 2 diabetes are also four times more likely to have myocardial infarction, heart disease or stroke than people without diabetes, and it’s imperative that people with Type 2 diabetes are aware of these risks.

“Nurses are really focused on providing education … helping to provide a deeper level of education and ensure that patients have the awareness and the knowledge that they need, to really to empower them to be aware and to do a better job managing their own disease,” Michael Radin, M.D., Novo Nordisk’s executive director, diabetes, medical affairs, said. “So that’s really the focus on nurses is because their purview really is around providing that education to the patient.”

Making the Connection is a U.S.-centric retooling of a program that Novo Nordisk originally launched internationally before deciding to address America’s growing Type 2 diabetes epidemic. Novo Nordisk is the driving force behind the program, and the pharma asked the PCNA to be a part of designing the curriculum to best meet the needs of the nurses taking the course.

The free online program is sectioned into five modules and then further broken down into three tracks aimed at three different nursing specialties. There are cardiac nurses—who obviously understand the cardiac aspect well but may not be as familiar with diabetes— the non-cardiac nurse who may really understand Type 2 diabetes but not the link to ASCVD, and the third group are nurse practitioners who are able to prescribe therapy. The goal is to close any education gaps so they are informed enough to prescribe the correct therapies.

Novo’s outreach of the program included an email blast to over 30,000 nurses; there are newsletters and flyers along with promotion at nursing events, and the PCNA is promoting the effort through its Facebook page, Twitter and in newsletter communications with its members. After completing the program, the users can download a pocket card highlighting the key concepts of the course.

Novo has been in the diabetes space for a while, but this program adds to the pharma’s recent forays into cardiovascular arena.

By Sharon Klahr



comments closed

Related News

December 10, 2023

Brain waves found in sleep shown to protect against epileptic activity

Life sciences

Researchers from University College London (UCL) have revealed that slow brain waves that occur during sleep could protect against increased brain excitability in patients living with epilepsy. In a study published in Nature Communications, researchers placed electrodes in 25 patients living with focal epilepsy to localise abnormal activity and inform surgical treatment.

December 10, 2023

Rousselot’s soft gel capsule stabilizing technology awarded USPTO patent

Life sciences

StabiCaps gelatin formulation enhances the release of active ingredients, including medications. In May 2022, the Darling Ingredients brand also received a patent from the European Patent Office for StabiCaps for all major European countries.

December 10, 2023

Roche to acquire obesity drug maker Carmot

Life sciences

In a move to participate in the race for anti-obesity drugs, Swiss pharma giant Roche has agreed to acquire Carmot Therapeutics, a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with the potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

How can we help you?

We're easy to reach